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Abstract: The identification of neurological disorders by next-generation sequencing (NGS)-based
gene panels has helped clinicians understand the underlying physiopathology, resulting in person-
alized treatment for some rare diseases. While the phenotype of distinct neurogenetic disorders
is generally well-known in childhood, in adulthood, the phenotype can be unspecific and make
the standard diagnostic approach more complex. Here we present three unrelated adults with var-
ious neurological manifestations who were successfully diagnosed using NGS, allowing for the
initiation of potentially life-changing treatments. A 63-year-old woman with progressive cognitive
decline, pyramidal signs, and bilateral cataract was treated by chenodeoxycholic acid following the
diagnosis of cerebrotendinous xanthomatosis due to a homozygous variant in CYP27A1. A 32-year-
old man with adult-onset spastic paraplegia, in whom a variant in ABCD1 confirmed an X-linked
adrenoleukodystrophy, was treated with corticoids for adrenal insufficiency. The third patient, a
28-year-old woman with early-onset developmental delay, epilepsy, and movement disorders was
treated with a ketogenic diet following the identification of a variant in SLC2A1, confirming a glucose
transporter type 1 deficiency syndrome. This case study illustrates the challenges in the timely
diagnosis of medically actionable neurogenetic conditions, but also the considerable potential for
improving patient health through modern sequencing technologies.
Keywords: neurogenetic disorders; cerebrotendinous xanthomatosis; X-linked adrenoleukodystrophy;
glucose transporter type 1 deficiency syndrome; treatable diseases; next-generation sequencing (NGS)
1. Introduction
Neurogenetic diseases represent a complex group of Mendelian disorders affecting the
central or peripheral nervous system with varied clinical presentations. For the majority
of them, therapeutic options are limited and mainly supportive [1]. However, progress
in the understanding of the underlying physiopathology has led to the development of
treatments, including dietary interventions, enzyme replacement therapy, specific medi-
cations, and others, which may remarkably improve the clinical course [2,3]. Currently, a
large proportion of these treatable conditions consist of inborn errors of metabolism (IEM).
A well-known example is phenylalanine hydroxylase deficiency, namely phenylketonuria
(PKU, OMIM 261600), in which a low phenylalanine diet implemented after birth prevents
the development of irremediable intellectual disability [4]. As in PKU, the benefit of thera-
peutic interventions in other treatable neurogenetic disorders is often larger when provided
early in the clinical course, averting irreversible damages to the nervous system [2]. Al-
though most of the IEM present soon after birth or during childhood, an increased number
of late-onset forms presenting in adulthood are now known [5].
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A prompt and accurate diagnosis is essential to providing the patient with potentially
life-changing treatment, as well as genetic counseling. In this regard, next-generation
sequencing (NGS) has provided new possibilities for the investigation of neurological
patients in combination with clinical data, neuroimaging, and laboratory findings. Never-
theless, the diagnostic process remains challenging, notably due to the complexity of the
field, with a large amount of extremely rare and recently discovered conditions [6].
Here, we document three unrelated adult patients in whom specific treatments were
provided after being diagnosed with cerebrotendinous xanthomatosis (CTX) (OMIM
213700), X-linked adrenoleukodystrophy (X-ALD) (OMIM 300100), and glucose trans-
porter type 1 deficiency syndrome (Glut1 DS) (OMIM 606777).
2. Materials and Methods
Molecular Genetic Testing
Genomic DNA was isolated from leukocytes and whole-exome sequencing (WES) was
carried out on an Illumina HiSeq 2500 sequencer (Illumina, Inc., San Diego, CA, USA) with
an Agilent SureSelectXT Human All Exon V7 capture kit (Agilent Technologies, Santa Clara,
CA, USA). Data processing, variants annotation, and filtering were performed as previously
described [7]. We analyzed a virtual panel (hereditary spastic paraplegia, 147 genes) in
patient 2, and the CYP27A1 and SLC2A1 genes in patients 1 and 3, respectively. Identified
variants were interpreted according to the American College of Medical Genetics and
Genomics (ACMG) variant classification guidelines [8]. They were subsequently confirmed
by Sanger sequencing. Segregation analysis by Sanger sequencing was performed in the
parents of proband 3.
3. Results
3.1. Proband 1
A 61-year-old woman presented with an 8-year history of progressive spastic tetra-
paresis, predominantly affecting lower extremities, and cerebellar ataxia, causing walking
difficulties. Subsequently, cognitive decline, including severe attention deficit, dysexecutive
syndrome, and memory loss, was documented. She also experienced chronic diarrhea,
which caused a 10 kg weight loss over 10 years. The review of her medical history revealed
that she underwent bilateral cataract surgery at age 44 and that she developed a bilateral
sensorineural hearing loss. She was born to healthy parents not known to be consan-
guineous. She had a twin sister (unknown zygosity) who developed a similar progressive
phenotype, including cognitive dysfunction, cerebellar ataxia, spastic tetraparesis, and
cataract from age 45, before her death from a cardiac disease at age 57 (Figure 1A). The
diagnosis of multiple sclerosis was suspected.
Brain MRI showed bilateral hyperintensities of the periventricular and semi-oval
centers white matter (Figure 1B). Furthermore, a nerve conduction study revealed a length-
dependent sensorimotor axonal polyneuropathy of lower limbs. Genetic testing excluded
trinucleotide repeat disorders including spinocerebellar ataxias (SCA) [1–3,6,7,9], Friedre-
ich ataxia, dentatorubral-pallidoluysian atrophy, and fragile X-associated tremor/ataxia
syndrome. Finally, the metabolic workup revealed increased levels of blood bile acids
(25 µmol/L; normal value (n.v.) 0–10) and of cholestanol (59.99 µmol/L; n.v. 0–15.45) com-
patible with the diagnosis of cerebrotendinous xanthomatosis (CTX). CTX was confirmed
by the identification of the pathogenic splice-site variant c.1184 + 1G>A in homozygosity
in intron 6 of the CYP27A1 gene.
Following the diagnosis, a focused clinical examination confirmed the absence of
tendinous xanthomas. Treatment with chenodeoxycholic acid was introduced, and at
the one-year follow-up, her blood cholestanol levels had normalized (13.3 µmol/L; n.v.
0–15.45). The diarrhea had disappeared, she had gained 4 kg, and a mild improvement in
her cognitive function was found.
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Figure 1. Family trees and phenotypic data of the three patients: (A,B) proband 1: family pedigree
(left panel) and axial views of brain MRI, FLAIR images showing non-confluent bilateral periven-
tricular and semi-oval center white matter hyperintensities (right panel); (C,D) proband 2: family
pedigree (left panel) and a picture of the mouth showing gingival hyperpigmentation (right panel);
(E,F) proband 3: family pedigree (left panel) and a photograph showing cervical dystonia with
right torticollis, as well as microcephaly. CTX, cerebrotendinous xanthomatosis; Glut1 DS, glucose
transporter type 1 deficiency syndrome; X-ALD, X-linked adrenoleukodystrophy.
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3.2. Proband 2
A 32-year-old man presented with a 5-year history of stiffness, spasms, and paresthesia
of lower limbs, with progressive gait difficulties and occasional falls. He also experienced
urinary urgencies and incontinence, as well as sexual dysfunction. Neurological examina-
tion revealed a tetrapyramidal syndrome predominantly affecting his lower extremities.
The proband had three older brothers, two of which experienced similar but even more
severe neurological symptoms (Figure 1C). His mother may have had (phasic) cervical
dystonia and the maternal grandmother was reported to have had late onset stiffness and
gait difficulties.
A nerve conduction study and brain and spine MRI were normal. The analysis of the
WES data focused on a hereditary spastic paraplegia gene panel (147 genes) allowed the
identification of the pathogenic variant c.1880T>A (p.Leu627His) in hemizygosity in the
ABCD1 gene, confirming the diagnosis of X-ALD. Elevated plasmatic very-long-chain fatty
acids (VLCFA) corroborated this diagnosis (C24/22: 1.68; n.v. 0.3–1.1, C26/22: 0.075; n.v.
0.002–0.025 and C26: 2.8 µmol/L; n.v. 0.3–1.9). The clinical phenotype was suggestive of
an adrenomyeloneuropathy (AMN), a typical adult-onset presentation of X-ALD.
Addison’s disease, being typically associated with AMN, informed a subsequent
clinical evaluation of the patient, looking more specifically for symptoms and signs of
adrenocortical insufficiency, which indeed revealed chronic fatigue, difficulty with weight
gain, cravings for salty food, and orthostatic hypotension. Gingival hyperpigmentation
was observed (Figure 1D). Addison’s disease was confirmed by documenting an elevated
plasmatic adrenocorticotropic hormone (ACTH) (167 ng/L, n.v. 9–50) and an abnormal
response to ACTH stimulation (cortisol level 1 h post i.v. injection of synacthen (0.25 mg):
353 nmol/L, n.v. > 500). Hormone replacement therapy with glucocorticoids (hydrocor-
tisone) and mineralocorticoids (fludrocortisone) was initiated. An emergency card for
Addison’s disease was given to the patient. Along with a genetic counselling, a family
information letter was provided to the patient to give his siblings the opportunity to be
evaluated at our clinic given their symptoms suggestive of AMN.
3.3. Proband 3
The proband was a 28-year-old woman born to healthy, unrelated parents (Figure 1E).
Hypotonia and progressive microcephaly were observed during the first months of life.
Her development was delayed (independent walking at age 2.5 years and language ac-
quisition at 4 years) and she received special education. From age 2, various movement
disorders including dystonic postures of fingers, dyskinesia, myoclonus, ataxia, and spas-
ticity of lower limbs were reported. During this period, she also developed epilepsy with
absence seizures and was treated with valproate. In addition, the patient presented with
paroxysmal episodes of variable semiology including stiffness of the right hemibody, or
hypotonia, causing difficulty walking, apathy, headache, nausea and vomiting, followed
by somnolence.
Extensive investigations performed in the first years of life did not produce a diagnosis.
In particular, a cerebral MRI at age 1 year revealed non-specific cortical white matter
anomalies. Her karyotype and the methylation of the region of chromosome 15, which is
involved in Angelman syndrome, were normal. Laboratory investigations excluded an
amino acid, organic acid, or a fatty acid β-oxidation disorder. However, hypoglycorrhachia
(1.5 mmol/L; n.v. 2.8–4.4 mmol/L) with abnormal cerebrospinal fluid (CSF)/blood glucose
ratio (0.25; n.v. 0.6) were identified. The CSF lactate concentration was also decreased
(0.92 mmol/L; n.v. 1.2–2.1). Despite these results, which are compatible with a glucose
transporter type 1 deficiency syndrome (Glut1 DS), no definitive diagnosis was made at
the time.
The patient was referred many years later (age 27 years) for a recently developed
quasi-fixed cervical dystonia (Figure 1F) without evidence of cervical or brain lesions.
Common infectious, metabolic, drug-induced, and autoimmune causes were excluded.
Symptomatic treatment with oral anticholinergic biperiden and focal injections of the
Genes 2021, 12, 695 5 of 7
botulinum toxin allowed for partial relief. The review of her childhood medical records
led to the suspicion of Glut1 DS. NGS analysis confirmed this diagnosis by identifying
the de novo pathogenic variant c.1259T>G in heterozygosity in the SLC2A1 gene, resulting
in the substitution of a highly conserved methionine to an arginine residue in position
420 in the 11th transmembrane segment. A ketogenic diet was initiated. At the 6 month
follow-up, the mother of the patient reported a clear improvement in cervical posturing
and a disappearance of hyperkinetic appendicular movements.
4. Discussion
We present three patients with IEM with different neurological manifestations in whom
an accurate diagnosis was achieved through NGS, allowing for personalized treatments.
Patient 1 and her deceased sister would have benefited from an earlier diagnosis
and treatment. The beneficial effect of chenodeoxycholic acid on neurological symptoms
is considered greater when prescribed earlier in the course of the disease by preventing
irreversible damage to the nervous system [10,11]. Interestingly, long diagnostic delays
appear to be common in CTX [12]. This may be due to the lack of awareness of this rare
disorder and to the variability in its phenotype. For example, in the spinal form of CTX,
xanthomas and other typical features may be absent [13]. Moreover, depending on the
health system, refusal of medical insurance providers to cover the costs of genetic testing
because of the alleged lack of therapeutic consequences may delay the diagnostic pro-
cess. Taken together, shortening the time to diagnosis is challenging in a field constantly
growing in complexity. For this reason, we think that the diagnostic process requires a
close collaboration between a multidisciplinary team of physicians who are familiar with
rare diseases, including clinical geneticists, metabolic specialists, neurologists, neurora-
diologists, and ophthalmologists. In addition, genetic databases and websites, as well
platforms for data sharing like Matchmaker Exchange, have become resources at least as
important as direct interactions with renowned experts in specific fields [14,15]. Finally,
the awareness of clinical, biological, and radiological red flags and symptom constellations
suggestive of a treatable neurogenetic disorder will contribute to reducing the time to
diagnosis [2]. For example, chronic diarrhea, juvenile cataracts, or tendon xanthomas in
patients with progressive neurological symptoms strongly point to CTX, as highlighted by
Mignarri et al. [12].
In patient 3, the diagnosis of Glut1 DS was delayed for decades, thereby preventing
the implementation of a ketogenic diet, a treatment shown to be effective in controlling
seizures and improving movement disorders [9,16,17]. This diagnostic wavering may be
explained by the sparse medical knowledge about this newly described syndrome in the
early 1990s when most of the investigations were conducted [18,19]. This illustrates the
necessity of periodical re-evaluations of patients with unexplained neurologic disorders.
Medical knowledge in clinical genetics is constantly progressing, driven by rapidly evolv-
ing diagnostic technologies. However, long diagnostic processes may be challenging in
adults with an early-onset neurodevelopmental disorder, as this category of patients is
often unable to seek medical attention by themselves and may receive limited attention
from the community. Consequently, they tend to be less thoroughly investigated than
children, which also implies that medical knowledge about the natural history and late-
onset complications of rare childhood-onset syndromes is often missing. Atypical adult
presentation different from the textbook phenotype defined in children may lead to a
missed diagnosis [20].
In patient 2, the clinical phenotype suggested hereditary spastic paraplegia, a large
group of diseases encompassing dozens of overlapping entities [21]. NGS was instrumental
to the diagnosis of X-ALD in this patient who had normal CNS imaging and no clinical
clues to this particular diagnosis prior to genetic testing. This diagnosis allowed for the
initiation of corticosteroid replacement therapy, which may prevent a potential adrenal
insufficiency crisis. Moreover, allogenic hematopoietic stem cell transplantation might be
indicated in patients developing the cerebral form of the disease [22].
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In all these cases, the availability and rapidity of NGS allowed for the confirmation of
the diagnosis. The genotype-first diagnostic process has become common with the recent
advances and increasing availability in clinical settings of genetic technologies, including
NGS and DNA microarray, bringing with it greater opportunities for diagnosing patients
and multiple family members [23,24]. Complementary to the classic phenotype to genotype
method, this approach in particular is indispensable in diagnosing atypical forms of a
given disease or conditions characterized by unspecific clinical features, such as cognitive
deficiency or autism. However, it poses the challenge of data interpretation knowing that
the NGS analysis of large gene panels can lead to the identification of variants of unknown
significance and incidental findings [8,25]. Current knowledge and international guidelines
for variant interpretation are helpful but still insufficient to remove a large amount of noise
when attempting to assign significance to particular findings [8,26].
Our case studies illustrate typical medical trajectories encountered by rare-disease
patients due to the complexity of their condition, but also the potential for improvement in
diagnosis delay and care due to expanding genetic technologies and awareness of this field
within the medical community. Although the increasing amount of available genetic data
from control populations and patients, together with the sophistication of diagnostic tools,
will facilitate the diagnostic process in the future, the development of emerging therapies
will further increase the importance of quick and accurate molecular diagnosis.
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